Bataille R, Vincent C, Revillard J P, Sany J
Eur J Cancer Clin Oncol. 1983 Aug;19(8):1075-80. doi: 10.1016/0277-5379(83)90030-5.
Serum beta 2m binding activity (S beta 2m-BA) was determined by a polyethylene glycol exclusion test of radiolabeled human beta 2m in 185 serum samples from 62 patients with multiple myeloma (MM). Elevated S beta 2m-BA was found in more than half of the samples from IgG myeloma taken before treatment or during progression of the disease but not during the plateau-phase. Conversely, elevated S beta 2m-BA was found in only one case of IgA myeloma, one case of monoclonal gammopathy of undetermined significance and none of the Bence Jones myelomas. S beta 2m-BA appears to be related to disease progression in IgG myeloma. The activity is supported by minute amounts of serum autoantibodies which are distinct from the monoclonal component. S beta 2m-BA was independent from serum beta 2m levels.
通过对62例多发性骨髓瘤（MM）患者的185份血清样本进行放射性标记人β2微球蛋白的聚乙二醇排除试验，测定血清β2微球蛋白结合活性（Sβ2m - BA）。在IgG骨髓瘤患者治疗前或疾病进展期采集的样本中，超过半数样本的Sβ2m - BA升高，但在平台期未升高。相反，仅在1例IgA骨髓瘤、1例意义未明的单克隆丙种球蛋白病患者中发现Sβ2m - BA升高，而在本-周蛋白骨髓瘤患者中均未发现。Sβ2m - BA似乎与IgG骨髓瘤的疾病进展有关。这种活性由微量血清自身抗体支持，这些自身抗体与单克隆成分不同。Sβ2m - BA与血清β2微球蛋白水平无关。
